Latest Insider Transactions at Mirati Therapeutics, Inc. (MRTX)
This section provides a real-time view of insider transactions for Mirati Therapeutics, Inc. (MRTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Mirati Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Mirati Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 20
2023
|
Charles M Baum Founder, President, and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
4,444
+2.5%
|
-
|
|
Jan 20
2023
|
Aaron I. Davis |
BUY
Grant, award, or other acquisition
|
Direct |
4,444
+8.55%
|
-
|
|
Jan 20
2023
|
Faheem Hasnain |
BUY
Grant, award, or other acquisition
|
Direct |
6,333
+29.62%
|
-
|
|
Jan 20
2023
|
Julie M Cherrington |
BUY
Grant, award, or other acquisition
|
Direct |
4,444
+50.0%
|
-
|
|
Jan 20
2023
|
Maria E Martinez |
BUY
Grant, award, or other acquisition
|
Direct |
4,444
+29.81%
|
-
|
|
Jan 20
2023
|
Henry J Fuchs |
BUY
Grant, award, or other acquisition
|
Direct |
4,444
+29.81%
|
-
|
|
Jan 20
2023
|
Laurie Stelzer Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,864
+24.09%
|
-
|
|
Jan 20
2023
|
Bruce L A Carter |
BUY
Grant, award, or other acquisition
|
Direct |
4,444
+29.81%
|
-
|
|
Jan 20
2023
|
Benjamin Hickey EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,394
+30.33%
|
-
|
|
Jan 20
2023
|
David D. Meek Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
89,379
+37.16%
|
-
|
|
Jan 20
2023
|
Jamie Christensen EVP & Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,864
+17.72%
|
-
|
|
Jan 20
2023
|
Shalini Sharp |
BUY
Grant, award, or other acquisition
|
Direct |
4,444
+32.07%
|
-
|
|
Jan 18
2023
|
Julie M Cherrington |
SELL
Open market or private sale
|
Direct |
2,546
-100.0%
|
$112,024
$44.66 P/Share
|
|
Jan 17
2023
|
Benjamin Hickey EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,566
-1.62%
|
$65,772
$42.38 P/Share
|
|
Jan 17
2023
|
Jamie Christensen EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,245
-1.13%
|
$94,290
$42.38 P/Share
|
|
Jan 17
2023
|
David D. Meek Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,179
-4.89%
|
$133,518
$42.38 P/Share
|
|
Jan 09
2023
|
Benjamin Hickey EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,088
-4.1%
|
$93,960
$45.37 P/Share
|
|
Jan 04
2023
|
Jamie Christensen EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,949
-1.91%
|
$89,654
$46.6 P/Share
|
|
Jan 04
2023
|
Charles M Baum Founder, President, and CEO |
SELL
Open market or private sale
|
Direct |
3,648
-2.12%
|
$167,808
$46.6 P/Share
|
|
Dec 21
2022
|
David D. Meek Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,616
-6.63%
|
$184,640
$40.41 P/Share
|
|
Dec 21
2022
|
Benjamin Hickey EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,248
-6.0%
|
$129,920
$40.41 P/Share
|
|
Dec 21
2022
|
Charles M Baum Founder, President, and CEO |
SELL
Open market or private sale
|
Direct |
9,092
-5.01%
|
$363,680
$40.42 P/Share
|
|
Dec 19
2022
|
David D. Meek Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,425
+33.73%
|
-
|
|
Dec 19
2022
|
Benjamin Hickey EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,149
+26.13%
|
-
|
|
Dec 19
2022
|
Charles M Baum Founder, President, and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
53,618
+22.8%
|
-
|
|
Dec 16
2022
|
Jamie Christensen EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,410
-2.31%
|
$103,630
$43.0 P/Share
|
|
Dec 02
2022
|
Jamie Christensen EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,726
-1.63%
|
$155,340
$90.19 P/Share
|
|
Nov 28
2022
|
Charles M Baum Founder, President, and CEO |
SELL
Open market or private sale
|
Direct |
69,256
-35.13%
|
$6,925,600
$100.0 P/Share
|
|
Nov 28
2022
|
Charles M Baum Founder, President, and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
69,256
+26.0%
|
$1,177,352
$17.41 P/Share
|
|
Nov 07
2022
|
Alan B. Sandler Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+50.0%
|
-
|
|
Sep 07
2022
|
Jamie Christensen EVP & Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,149
+15.29%
|
-
|
|
Aug 12
2022
|
Bruce L A Carter |
SELL
Open market or private sale
|
Direct |
10,000
-38.35%
|
$850,000
$85.5 P/Share
|
|
Aug 12
2022
|
Bruce L A Carter |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+38.43%
|
$270,000
$27.0 P/Share
|
|
Jun 01
2022
|
Laurie Stelzer Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
57,798
+50.0%
|
-
|
|
May 23
2022
|
Jamie Christensen EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
624
-0.71%
|
$39,312
$63.54 P/Share
|
|
Feb 11
2022
|
Henry J Fuchs |
SELL
Open market or private sale
|
Direct |
11,000
-24.64%
|
$1,155,000
$105.63 P/Share
|
|
Feb 11
2022
|
Henry J Fuchs |
BUY
Exercise of conversion of derivative security
|
Direct |
11,000
+28.0%
|
$220,000
$20.54 P/Share
|
|
Jan 19
2022
|
Julie M Cherrington |
SELL
Open market or private sale
|
Direct |
1,475
-36.68%
|
$171,100
$116.07 P/Share
|
|
Jan 18
2022
|
Benjamin Hickey EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
627
-1.76%
|
$75,240
$120.48 P/Share
|
|
Jan 18
2022
|
Charles M Baum Founder, President, and CEO |
SELL
Open market or private sale
|
Direct |
2,517
-1.93%
|
$302,040
$120.48 P/Share
|
|
Jan 18
2022
|
Charles M Baum Founder, President, and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,703
+2.76%
|
$99,981
$27.0 P/Share
|
|
Jan 18
2022
|
Jamie Christensen EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
627
-0.71%
|
$75,240
$120.51 P/Share
|
|
Jan 18
2022
|
Vickie S Reed SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
533
-3.35%
|
$63,960
$120.48 P/Share
|
|
Jan 14
2022
|
Shalini Sharp |
BUY
Grant, award, or other acquisition
|
Direct |
2,546
+33.87%
|
-
|
|
Jan 14
2022
|
Aaron I. Davis |
BUY
Grant, award, or other acquisition
|
Direct |
2,546
+5.58%
|
-
|
|
Jan 14
2022
|
Julie M Cherrington |
BUY
Grant, award, or other acquisition
|
Direct |
2,546
+38.77%
|
-
|
|
Jan 14
2022
|
David D. Meek Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,057
+50.0%
|
-
|
|
Jan 14
2022
|
Maria E Martinez |
BUY
Grant, award, or other acquisition
|
Direct |
2,546
+29.72%
|
-
|
|
Jan 14
2022
|
Craig A Johnson |
BUY
Grant, award, or other acquisition
|
Direct |
2,546
+29.72%
|
-
|
|
Jan 14
2022
|
Henry J Fuchs |
BUY
Grant, award, or other acquisition
|
Direct |
2,546
+29.72%
|
-
|